Your session is about to expire
← Back to Search
Intra-arterial Cetuximab + Intra-arterial Mannitol + Hypofractionated re-irradiation for Brain Tumor
This trial is testing a new way to treat brain cancer that involves surgery, radiation, and chemotherapy. The goal is to see if this new method is safe and effective.
- Brain Cancer
- Anaplastic Astrocytoma
- Brain Tumor
- Brain Metastases
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have signs of leptomeningeal disease on imaging tests.You have had an allergic reaction to CTX in the past.You finished chemotherapy or radiation treatment less than 6 months ago.You have been diagnosed with a type of brain cancer called glioblastoma multiforme, anaplastic astrocytoma, or anaplastic oligoastrocytoma that has come back or not responded to treatment.You have been diagnosed with a specific type of cancer that shows high levels of EGFR.You need to have at least one confirmed and measurable tumor.You must be able to perform daily activities at least 60% of the time and have an expected survival of at least three months.You need to have enough white blood cells, neutrophils, and platelets in your blood. If you are taking Coumadin, you need to have a higher platelet count.Your blood tests must show that your bilirubin, AST or ALT, and creatinine levels are not too high.Your blood clotting tests should not be more than 1.5 times the normal range before enrolling in the study.You have not already tried the standard treatment known as the Stupp protocol.
- Group 1: Intra-arterial Cetuximab with Re-Irradiation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Intra-arterial Cetuximab been the subject of previous research efforts?
"Currently, 129 trials are being conducted to investigate the efficacy of Intra-arterial Cetuximab. 34 of these active studies have moved into Phase 3 - with Dresden and Arizona hosting a large majority of them. However, across the world 5560 different sites are researching this medication."
Could you please explain the purpose of Intra-arterial Cetuximab?
"Intra-arterial Cetuximab is a traditional medication used to measure glucose tolerance. Additionally, it can be utilized as a treatment for radiation therapy, glomerular filtration rate measurement, kidney failure, and other acute conditions."
Has Intra-arterial Cetuximab been officially sanctioned by the FDA?
"There is some evidence suggesting Intra-arterial Cetuximab's safety, so it was scored a 2. Unfortunately, there is no prior clinical data to support efficacy at this time."
How many test subjects are involved in the experiment?
"Affirmative. According to clinicaltrials.gov, this research is actively enrolling participants that meet the criteria; it was first posted on May 1st 2016 and last updated October 17th 2022 in preparation for recruiting 37 people at one location."
Are there vacancies available for those wishing to participate in this experiment?
"According to clinicaltrials.gov, the trial is still open for patient enrollment and has been so since it was initially posted on May 1st 2016. Its data was last revised October 17th 2022."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Lenox Hill Brain Tumor Center: < 48 hours
Average response time
- < 2 Days
Share this study with friends